- Home
- ZTEK vs CGEN Comparison
ZTEK vs CGEN Comparison
Compare ZTEK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- CGEN
- Stock Information
- Founded
- ZTEK 2008
- CGEN 1993
- Country
- ZTEK Canada
- CGEN Israel
- Employees
- ZTEK N/A
- CGEN N/A
- Industry
- ZTEK Major Chemicals
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZTEK Industrials
- CGEN Health Care
- Exchange
- ZTEK Nasdaq
- CGEN Nasdaq
- Market Cap
- ZTEK 165.9M
- CGEN 167.4M
- IPO Year
- ZTEK N/A
- CGEN 2000
- Fundamental
- Price
- ZTEK $1.16
- CGEN $1.76
- Analyst Decision
- ZTEK
- CGEN
- Analyst Count
- ZTEK 0
- CGEN 0
- Target Price
- ZTEK N/A
- CGEN N/A
- AVG Volume (30 Days)
- ZTEK 33.2K
- CGEN 181.3K
- Earning Date
- ZTEK 08-13-2025
- CGEN 08-05-2025
- Dividend Yield
- ZTEK N/A
- CGEN N/A
- EPS Growth
- ZTEK N/A
- CGEN N/A
- EPS
- ZTEK N/A
- CGEN N/A
- Revenue
- ZTEK $607,016.00
- CGEN $27,589,000.00
- Revenue This Year
- ZTEK N/A
- CGEN N/A
- Revenue Next Year
- ZTEK N/A
- CGEN $173.80
- P/E Ratio
- ZTEK N/A
- CGEN N/A
- Revenue Growth
- ZTEK 2826.26
- CGEN N/A
- 52 Week Low
- ZTEK $0.50
- CGEN $1.13
- 52 Week High
- ZTEK $1.84
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- ZTEK 30.38
- CGEN 59.85
- Support Level
- ZTEK $1.03
- CGEN $1.62
- Resistance Level
- ZTEK $1.16
- CGEN $1.81
- Average True Range (ATR)
- ZTEK 0.10
- CGEN 0.08
- MACD
- ZTEK -0.03
- CGEN 0.00
- Stochastic Oscillator
- ZTEK 17.02
- CGEN 78.26
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.